• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3 filed by new insider Lebowitz Peter F

    3/26/26 5:12:54 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BBOT alert in real time by email
    SEC FORM 3SEC Form 3
    FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0104
    Estimated average burden
    hours per response:0.5
    1. Name and Address of Reporting Person*
    Lebowitz Peter F

    (Last)(First)(Middle)
    BRIDGEBIO ONCOLOGY THERAPEUTICS, INC.
    256 EAST GRAND AVENUE, SUITE 104

    (Street)
    SOUTH SAN FRANCISCO CALIFORNIA 94080

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Date of Event Requiring Statement (Month/Day/Year)
    03/24/2026
    3. Issuer Name and Ticker or Trading Symbol
    BridgeBio Oncology Therapeutics, Inc. [ BBOT ]
    3a. Foreign Trading Symbol
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    XDirector10% Owner
    Officer (give title below)Other (specify below)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    Remarks:
    Exhibit 24 - Power of Attorney
    No securities are beneficially owned.
    /s/ Aaron Chan, Attorney-in-Fact03/26/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 3: SEC 1473 (03-26)
    Get the next $BBOT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBOT

    DatePrice TargetRatingAnalyst
    2/11/2026$23.00Buy
    Stifel
    1/9/2026$24.00Outperform
    Raymond James
    12/5/2025$20.00Overweight
    Morgan Stanley
    9/17/2025$25.00Outperform
    Leerink Partners
    9/15/2025$27.00Buy
    H.C. Wainwright
    8/15/2025$21.00Overweight
    Piper Sandler
    More analyst ratings

    $BBOT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Lebowitz Peter F

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    3/26/26 5:14:24 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Lebowitz Peter F

    3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    3/26/26 5:12:54 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Mehra Uneek was granted 23,330 shares (SEC Form 4)

    4 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Issuer)

    3/12/26 4:58:25 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

    SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today announced multiple presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026 being held on April 17-22, 2026, in San Diego, California. The abstracts released today can be found on the AACR website here. Details on the presentations are as follows: Title: The RAS: PI3Kα breaker BBO-10203 inhibits PI3Kα/AKT activity in HER2+ models through non-canonical RAS signaling blockadeSession Category: Experimental and Molecular TherapeuticsSession Title:

    3/18/26 4:05:00 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BBOT Announces Publication in Cancer Discovery Highlighting Preclinical Data Demonstrating BBO-11818 is a Potent and Selective panKRAS Inhibitor

    BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the ON and OFF states, has high selectivity over HRAS and NRAS, and displays strong activity in KRAS mutant preclinical models, including KRASG12D and KRASG12V BBO-11818 showed significant tumor growth inhibition across multiple tumor types in preclinical models and demonstrated enhanced efficacy in combination with other anti-tumor agents, including BBO-10203, BBOT's selective RAS:PI3Kα breaker Preliminary clinical data from the BBO-11818 Phase 1 KONQUER-101 trial showed encouraging anti-tumor activities and differentiated safety, with additional data expected in the second half of 2026; interna

    3/6/26 10:07:35 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BBOT Reports Fourth Quarter and Full Year 2025 Financial Results and Update on Corporate Progress

    BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three clinical-stage small molecule inhibitors targeting the RAS pathway.Announced encouraging preliminary safety and efficacy data across all three programs: BBO-8520's differentiated efficacy and safety profile as monotherapy and at active doses in combination with pembrolizumab with a potentially differentiated liver toxicity profile, BBO-11818 producing the first publicly disclosed partial response in PDAC as a panKRAS inhibitor, and BBO-10203 showing no hyperglycemia without HbA1c restriction — establishing the clinical foundation for differentiated combination strategies, including BBOT's intern

    3/5/26 4:05:00 PM ET
    $BBOT
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Stifel initiated coverage on BridgeBio Oncology Therapeutics with a new price target

    Stifel initiated coverage of BridgeBio Oncology Therapeutics with a rating of Buy and set a new price target of $23.00

    2/11/26 7:51:34 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Raymond James initiated coverage on BridgeBio Oncology Therapeutics with a new price target

    Raymond James initiated coverage of BridgeBio Oncology Therapeutics with a rating of Outperform and set a new price target of $24.00

    1/9/26 9:02:41 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley initiated coverage on BridgeBio Oncology Therapeutics with a new price target

    Morgan Stanley initiated coverage of BridgeBio Oncology Therapeutics with a rating of Overweight and set a new price target of $20.00

    12/5/25 8:44:53 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    SEC Filings

    View All

    SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.

    424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    3/26/26 4:54:24 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by BridgeBio Oncology Therapeutics Inc.

    8-K - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    3/26/26 4:52:18 PM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by BridgeBio Oncology Therapeutics Inc.

    424B3 - BridgeBio Oncology Therapeutics, Inc. (0001869105) (Filer)

    3/6/26 6:01:08 AM ET
    $BBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BBOT
    Leadership Updates

    Live Leadership Updates

    View All

    BBOT Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

    BBOT debuted as a publicly traded company focused on optimized target coverage for patients with tumors driven by RAS and PI3Kα and a synergistic portfolio that is designed to enable targeted KRAS combinations Advanced three ongoing Phase 1 clinical trials, with clinical data readouts from each program expected in 2026Cash runway expected to fund BBOT operations into 2028Appointed industry veteran Uneek Mehra as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the third quar

    11/12/25 4:05:00 PM ET
    $BBOT
    $HLXB
    Biotechnology: Pharmaceutical Preparations
    Health Care